| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
95%
|
USAspending awards from Department of Veterans Affairs: $600,808 across 10 awards. 36C25025P0025 PHARMACEUTICAL DRUG; 36C26226N0373 EMERGENCY THIOLA 100 MG TABLETS; 36C26124N0539 SPARSENTAN 400MG TAB… |
| FILSPARI |
FILSPARI |
92%
|
The Company sells FILSPARI to two direct-to-patient specialty pharmacies in the United States |
| PATIENTS |
PATIENTS |
92%
|
The Company sells its tiopronin products to patients and pharmacies, with distribution facilitated through a single direct-to-patient distributor |
| SPECIALTY-PHARMACIES |
SPECIALTY-PHARMACIES |
92%
|
The Company sells its products to specialty pharmacies and through direct-to-patient distributors worldwide |
| THIRD-PARTY-PAYERS |
THIRD-PARTY-PAYERS |
92%
|
The Company receives payments from sales of its tiopronin products, primarily through third party payers |
| BMY |
Bristol-Myers Squibb Company |
72%
|
sh share-based compensation, license fees, milestones under license agreements, costs paid to third-party contractors to perform research, conduct clinical trials, and develop drug materials and deli… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from TVTX graph: sh share-based compensation, license fees, milestones under license agreements, costs paid to third-party contractors … |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
Reciprocal relationship from BMYMP graph: Reciprocal relationship from TVTX graph: sh share-based compensation, license fees, milestones under license agreements, costs paid to third-party contractor… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
sh share-based compensation, license fees, milestones under license agreements, costs paid to third-party contractors to perform research, conduct clinical trials, and develop drug materials and deli… |
| CSLLY |
CSL Limited |
72%
|
Reciprocal relationship from CSLLY graph: Reciprocal relationship from TVTX graph: s of effective sales personnel; • lack of complementary products to be offered by sales personnel, which may put us … |
| CSLLY |
CSL Limited |
72%
|
s of effective sales personnel; • lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies that have more extensive produc… |
| MIRM |
Mirum Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from MIRM graph: Reciprocal relationship from TVTX graph: Reciprocal relationship from MIRM graph: 808) (“Topic 808”) and determines whether such arrangements involve joint op… |
| ORANY |
ORANY |
72%
|
s of effective sales personnel; • lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies that have more extensive produc… |
| ORANY |
ORANY |
72%
|
Reciprocal relationship from ORANY graph: Reciprocal relationship from TVTX graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from TVTX graph: s of effective sales personnel; •… |
| VERA |
Vera Therapeutics, Inc. |
72%
|
Reciprocal relationship from VERA graph: experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance that we will not face shortages from one or … |
| COORDINATION-GROUP |
COORDINATION-GROUP |
62%
|
to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. This includes claims made to programs w… |
| PHARMAKRYSTO-LIMITED |
PHARMAKRYSTO-LIMITED |
62%
|
equity securities of Renalys at any time prior to the top-line results of the Phase 3 trial in Japan (“Buyout Right”). Under the Renalys License Agreement, Renalys will be responsible for all develop… |
| TORRENT-PHARMACEUTICALS-LIMITED |
TORRENT-PHARMACEUTICALS-LIMITED |
62%
|
ing the basis for cooperation at EU level for joint clinical assessments in these areas. The Regulation foresees a three-year transitional period and will permit EU Member States to use common HTA to… |
